logo
A "who's who" of mega-cap shareholders & partners

A "who's who" of mega-cap shareholders & partners

Updated August 2024

Market/Symbol

LON:ONT

Price

£1.4760.07%

Market Cap

£1.4b

PE Ratio

0

Average Volume

2.2m

Pricing delayed 2 hours. Nov 21, 2024 9:00 AM

Investment Thesis

Oxford Nanopore Technologies

Oxford Nanopore Technologies is a UK-based leader in DNA/RNA sequencing technology. It is the only producer of portable, handheld gene-sequencing devices worldwide. Its technology can read more of the genome, faster and more accurately than any competitor. ONT devices are used in over 100 countries across sectors like healthcare, agriculture, environmental science, and research. Key applications include pathogen surveillance (e.g., COVID), personalised medicine, and genetic research. Oxford Nanopore enables the analysis of anything, anywhere, by anyone. Real-time access to genomic data promises vast market opportunities for ONT and its mega-cap partners.

Follow the Experts

Quickly navigate key insights from industry experts and leverage their knowledge and market intelligence.

Oxford Nanopore has developed a new generation of sensing technology, providing DNA/RNA sequencing information using a range of devices from the pocket size to ultra-high output devices.

Novo Holdings

Novo Nordisk Investment firm

Get Deeper Insights

What the Pro's Are Asking

Here are the questions that professional investors are asking before making an investment decision.

Clinical Diagnostics, Infectious Disease Monitoring, Environmental DNA Analysis, Agricultural Research, Microbiome Studies, Genomics Research, Ancient DNA Studies, Forensic Analysis and Space Research.
Get real time
updates
logo
Company News
logo
Expert insight
logo
Market news

External Insights

A curated collection of third-party content relevant to the company and sector to help inform your investment decision.

Research

Team

team member

Gordan Sanghera

Chief Executive Officer

Gordon Sanghera is a Co-Founder of Oxford Nanopore. He was appointed CEO in May 2005 and has led the company through multiple finance rounds, and in 2021, a listing on the London Stock Exchange. Dr Sanghera’s PhD in bioelectronic technology was followed by a career at MediSense where he held positions including VP World Wide Marketing, Research Director and Manufacturing Process Development Director.
team member

Nick Keher

Chief Financial Officer

Nick is an experienced life sciences CFO, having previously served as CFO of Clinigen Group and Benevolent AI. Before his CFO roles, he gained extensive experience in the life sciences industry serving as Managing Director and Head of the European healthcare equity research team at Royal Bank of Canada (RBC) before that held roles at Investec and GSK after switching from practising pharmacy
team member

Dr Spike Willcocks

Chief Strategy Officer

Spike joined Oxford Nanopore at the start of 2006, leading the Corporate and Business development function, and now is the company's Chief Strategy Officer. He studied at The University of Oxford and completed a Dphil in Biochemistry, after this he worked for the intellectual property investment business "IP Group" in 2001 as an early employee
team member

Clive Brown

Chief Technology, Innovation and Product Officer

Clive leads the innovation of breakthrough technologies and product development, that are designed to enable the analysis of anything, by anyone, anywhere. Clive has held a variety of roles in Genomics and Genetic R&D, he has also played a key role in developing the Solexa NGS platform that is now the basis for Illumina's sequencing technology

Let's Connect

Complete the form to contact the investor relations team.
Follow our socials
We post updates and content every day on the companies we showcase. Follow to be sure you don't miss anything!
Join our mailing list
To keep up-to-date with the companies showcased
You can also email us at

logoAny questions?

Contact: Nirav Karia -

nirav.karia@curationcorp.com

General disclaimer and copyright

This showcase has been commissioned by the Business and prepared and issued by Curation, in consideration of a fee payable by the business. Fees are paid in cash without recourse. Curation may seek additional fees for the provision of content and related IR services for the client but does not get remunerated for any investment banking services.Accuracy of content: All information used in the publication of this showcase has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this showcase and have not sought for this information to be independently verified. Opinions contained in this showcase represent those of Curation at the time of publication. Forward-looking information or statements in this report may contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.Exclusion of Liability: To the fullest extent allowed by law, Curation shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this showcase.No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Curation's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.Investment in securities mentioned: Curation does not itself hold any positions in the securities mentioned in this report, nor the analysts who responsible for compiling this showcase. However, the respective directors, officers, employees and contractors of Curation may have a position in any or related securities mentioned in this showcase, subject to Curation's policies on personal dealing and conflicts of interest.

United Kingdom

This document is prepared and provided by Curation for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Curation relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This showcase is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Curation does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.